See more : JSC National Atomic Company Kazatomprom (KAP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Royalty Pharma plc (RPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Royalty Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chai Watana Tannery Group Public Company Limited (CWT.BK) Income Statement Analysis – Financial Results
- Bewith, Inc. (9216.T) Income Statement Analysis – Financial Results
- Dominion Minerals Limited (DLM.AX) Income Statement Analysis – Financial Results
- Ludan Engineering Co. Ltd (LUDN.TA) Income Statement Analysis – Financial Results
- PT. MNC Studios International Tbk. (MSIN.JK) Income Statement Analysis – Financial Results
Royalty Pharma plc (RPRX)
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Cost of Revenue | 560.66M | 5.67M | 23.00M | 88.11M | 1.02B | 135.96M | 33.27M | 0.00 | 0.00 |
| Gross Profit | 1.79B | 2.23B | 2.27B | 2.03B | 794.93M | 1.66B | 1.56B | 1.88B | 1.65B |
| Gross Profit Ratio | 76.19% | 99.75% | 99.00% | 95.85% | 43.82% | 92.43% | 97.92% | 100.00% | 100.00% |
| Research & Development | 52.00M | 177.11M | 200.08M | 26.00M | 83.04M | 392.61M | 117.87M | 91.02M | 98.38M |
| General & Administrative | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 69.51M | 121.42M |
| Other Expenses | 560.66M | 909.91M | 475.84M | 319.00M | -995.40M | -1.52M | -1.62M | -925.80M | -570.18M |
| Operating Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.09B | 789.98M |
| Cost & Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.15B | 858.14M |
| Interest Income | 72.29M | 78.34M | 53.54M | 28.38M | 22.33M | 24.44M | 6.76M | 0.00 | 0.00 |
| Interest Expense | 187.19M | 187.96M | 166.14M | 157.00M | 268.57M | 279.96M | 247.34M | 238.92M | 224.42M |
| Depreciation & Amortization | 395.13M | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M | 33.27M | 68.20M | 68.16M |
| EBITDA | 1.89B | 928.56M | 1.45B | 1.68B | 2.65B | 1.40B | 972.96M | 1.07B | 862.44M |
| EBITDA Ratio | 80.15% | 43.95% | 64.73% | 88.69% | 145.37% | 78.76% | 71.46% | 42.14% | 52.19% |
| Operating Income | 1.49B | 977.50M | 1.43B | 1.60B | 2.62B | 1.36B | 939.69M | 722.87M | 794.28M |
| Operating Income Ratio | 63.37% | 43.69% | 62.49% | 75.16% | 144.59% | 76.02% | 58.81% | 38.50% | 48.07% |
| Total Other Income/Expenses | 207.94M | -77.00M | -189.51M | 106.56M | -161.76M | 153.41M | 403.49M | 39.02M | -35.57M |
| Income Before Tax | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B | 1.34B | 761.90M | 758.71M |
| Income Before Tax Ratio | 72.20% | 10.28% | 54.21% | 80.21% | 135.67% | 84.57% | 84.06% | 40.58% | 45.91% |
| Income Tax Expense | 0.00 | 187.23M | 762.45M | 1.15B | 349.33M | 433.37M | 542.66M | 195.99M | 177.28M |
| Net Income | 1.13B | 42.83M | 478.75M | 495.20M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| Net Income Ratio | 48.20% | 1.91% | 20.91% | 23.34% | 129.45% | 76.76% | 75.72% | 30.14% | 35.19% |
| EPS | 3.41 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| EPS Diluted | 2.53 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| Weighted Avg Shares Out | 447.60M | 437.96M | 414.79M | 375.44M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
| Weighted Avg Shares Out (Dil) | 602.90M | 437.97M | 414.80M | 375.46M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
I'm on the hunt for ‘Strong Buy' biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks.
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00...
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug...
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of...
Source: https://incomestatements.info
Category: Stock Reports